Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies
Krina K. Patel(University of Vermont), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Craig C. Hofmeister(The Ohio State University), Taewoong Choi(Duke University), Sohail A. Chaudhry(Nektar Therapeutics (United States)), Hayder Saeed(University of Kentucky), Nina Shah(The University of Texas MD Anderson Cancer Center), Mario Q. Marcondes(Nektar Therapeutics (United States)), Mary Tagliaferri(Nektar Therapeutics (United States)), Alan Tan(Unknown), Julio C. Chávez(Moffitt Cancer Center), Christie Fanton(Nektar Therapeutics (United States)), Cameron J. Turtle(The University of Sydney), Heng Xu(Nektar Therapeutics (United States)), Xiaoli Wang(First Affiliated Hospital of Jiangxi Medical College), Andrew J. Cowan(University of Washington), Zachary Lee(Nektar Therapeutics (United States)), Neha Dixit(Nektar Therapeutics (United States)), Matthew J. Pianko(University of Michigan), Mitul Gandhi(Virginia Cancer Specialists), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k